ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0621

Altered Immunological Circadian Rhythms and the Effect of Treatment with Glucocorticoids on Circadian Rhythms of Immune Cells in Patients with Rheumatoid Arthritis: Bring Back the Rhythm

Siska Wilantri1, Cindy Strehl1, Dimas Abdirama1, Timo Gaber1, Robert Biesen2 and Frank Buttgereit1, 1Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, 2Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany

Meeting: ACR Convergence 2022

Keywords: Biostatistics, corticosteroids, cytokines, innate immunity, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Etiology and Pathogenesis Poster

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Clinical symptoms of rheumatoid arthritis (RA), including pain, joint stiffness, and swelling, exhibit a distinct circadian rhythm that exacerbates in the early morning in most patients. This is primarily attributed to the circadian variation of the key pro-inflammatory cytokines IL-6 and TNFα, which peak before the worsening of symptoms. Synthetic glucocorticoids (GCs) are among the most commonly prescribed medications for RA. GCs affect the vast majority of immune cells. GCs inhibit the expression of numerous cytokines, such as IL-1, TNFα, and IL-6. GCs are also known to influence the circadian rhythms of immune cells. For instance, they regulate the rhythm of circulating CD4+ and CD8+ T cells via CXCR4. For optimization of diagnosis and treatment strategies for RA, we performed a clinical study comparing the circadian rhythms of healthy donors (HD) and patients with RA. In addition, we investigated the effect of GC treatment on the circadian immune rhythms of RA patients.

Methods: We recruited 12 HD and 13 patients (female, post-menopausal) with active RA (DAS28≥4.0) of whom 5 had ongoing treatment with GCs. A week prior to the study day, their biological clocks were synchronized through a scheduled sleep and mealtime routine. On the study day, they were provided with regular meals, permitted to consume snacks ad libitum, and engaged in passive activities. We collected blood samples every two hours for 24 hours. Using TruCount (flow cytometry), qPCR, and a multiplex suspension assay, the absolute number of circulating immune cells, clock gene expression in monocytes, and serum cytokine levels were assessed, respectively.

Results: Circadian rhythms of regulatory T cells were shifted and the number was substantially lower in RA (Table 1). CD8+ T cells, CD14+ monocytes, and CD19+ B cells lost their rhythms in RA, but these were restored in patients with GC treatment. NK and NK T cells, which were not circadian in HD, displayed “inflammatory circadian rhythms” in RA. In GC-treated patients, these rhythms were diminished. In monocytes, gene expressions of BMAL1, PER1, PER2, and REVERBA were circadian in HD but not in RA. Rhythms of PER2 and REVERBA were restored in GC-treated patients. CRY1 expression exhibited diurnal variation in RA but not in HD. Serum IL-6 exhibited circadian rhythms in both groups, and GC therapy had no discernible effect on IL-6. Serum IL-4, IL-5, and MIP3α were circadian in HD but not in RA patients. The following cytokines were notably elevated in RA-patients: IFNγ, MIP1α, MIP1β, IL-1β, IL-2, IL-17A, and IL-21. GC reduced the expression of IL-10 significantly in RA.

Conclusion: In patients with RA, we observed altered circadian rhythms and the emergence of “inflammatory rhythms”. We demonstrated that GC treatment in non-responder patients resulted in three distinct effects on the circadian rhythms of immune cells: restoration, amplification, and attenuation. In conclusion, these findings offer novel insights into the pathophysiology of circadian rhythms in RA, which could be used to optimize diagnosis and treatment. The limitations of this study include a small sample size and gender-biased samples. Cortisol and melatonin measurements are impending.

Supporting image 1


Disclosures: S. Wilantri, None; C. Strehl, None; D. Abdirama, None; T. Gaber, None; R. Biesen, Novartis; F. Buttgereit, Horizon Therapeutics, Roche, Abbvie, AstraZeneca, Gruenenthal, Mundipharma, Pfizer.

To cite this abstract in AMA style:

Wilantri S, Strehl C, Abdirama D, Gaber T, Biesen R, Buttgereit F. Altered Immunological Circadian Rhythms and the Effect of Treatment with Glucocorticoids on Circadian Rhythms of Immune Cells in Patients with Rheumatoid Arthritis: Bring Back the Rhythm [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/altered-immunological-circadian-rhythms-and-the-effect-of-treatment-with-glucocorticoids-on-circadian-rhythms-of-immune-cells-in-patients-with-rheumatoid-arthritis-bring-back-the-rhythm/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/altered-immunological-circadian-rhythms-and-the-effect-of-treatment-with-glucocorticoids-on-circadian-rhythms-of-immune-cells-in-patients-with-rheumatoid-arthritis-bring-back-the-rhythm/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology